AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Companies agree to co-develop, co-promote drug. (sparfloxacin) (Warner-Lambert, Rhone-Poulenc Rorer)
Warner-Lambert Company and Rhone-Poulenc Rorer Inc. (RPR) announced an agreement that will allow RPR to co-develop and co-promote the advanced quinolone antibacterial sparfloxacin in the U.S. and Canada.
Warner-Lambert will continue to study sparfloxacin in the U.S. for the treatment of Mycobacterium avium complex (MAC) in patients with AIDS. MAC is the most common bacterial infection in AIDS patients.
Sparfloxacin will soon enter Phase III clinical trials in the U.S. as a treatment for community acquired infections. The compound's investigational indications are community acquired pneumonia, acute …
-
- Battered but battling back.
-
Magazine article from: Philadelphia Business Journal
GEORGE, JOHN
November 10, 2000
700+ words
-
- Lung Cancer.(Pamphlet)
-
Newspaper article from: New Medical Therapies -- Lung Cancer
January 1, 2000
700+ words
-
- Clinical Research Focuses on Chemotherapy and Vaccines.
-
Newspaper article from: New Medical Therapies -- Lung Cancer
ALLEN, WHITNEY
January 1, 2000
700+ words
